FGF19 and hepatocellular carcinoma: These two studies are promising for ~15% HCC patients who harbor genomic amplification of FGF19 gene in chromosome 11q13.3, and mandates evaluation of fisogatinib in phase III trials in a larger cohort of patients [161].